Welcome to LookChem.com Sign In|Join Free
  • or
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)thio]-2-methyl-propanamide is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

906008-93-3

Post Buying Request

906008-93-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

906008-93-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 906008-93-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,6,0,0 and 8 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 906008-93:
(8*9)+(7*0)+(6*6)+(5*0)+(4*0)+(3*8)+(2*9)+(1*3)=153
153 % 10 = 3
So 906008-93-3 is a valid CAS Registry Number.

906008-93-3Relevant academic research and scientific papers

Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists

Kandil, Sahar,Lee, Kok Yung,Davies, Laurie,Rizzo, Sebastiano A.,Dart, D. Alwyn,Westwell, Andrew D.

, p. 49 - 60 (2019/02/12)

Deshydroxy propioanilides were synthesised by Michael addition reaction between substituted thiophenols onto four different phenylacrylamide derivatives to give twenty-three novel deshydroxy bicalutamide derivatives lacking the central hydroxyl group. The antiproliferative activities of these compounds were evaluated against human prostate cancer cell lines and thirteen compounds showed better inhibitory activities (IC50 = 2.67–13.19 μM) compared to bicalutamide (IC50 = 20.44 μM) in LNCaP. Remarkably, novel double branched bicalutamide analogues (27 and 28) were isolated as major by-products and found to have the best activity across three human prostate cancer cell lines (LNCaP, VCaP and PC3). The most active compound 28 shows sub-micromolar activity (IC50 = 0.43 μM in LNCaP), which represents more than 40-fold improvement over the clinical anti-androgen bicalutamide (IC50 = 20.44 μM) and a more than 3 fold improvement over enzalutamide (IC50 = 1.36 μM). Moreover, strong reduction of PSA expression in LNCaP cells upon treatment with compounds 27, 28 and 33 was observed during qPCR analysis, confirming their AR antagonist activity. Molecular modelling studies revealed a novel binding mode of these structurally distinct double branched analogues within the ligand binding domain (LBD) of the androgen receptor.

Synthesis of potential impurities of bicalutamide

Bhise, Nandu Baban,Sathe, Dhananjay Govind,Radhakrishanan, Tarur,Deore, Raviraj

experimental part, p. 1516 - 1526 (2009/10/17)

Bicalutamide is an oral nonsteroidal, anti-androgen drug used for prostate cancer. It binds to the androgen receptor. During the bulk synthesis of bicalutamide, various impurities are formed. The present work details the development of simple processes for the preparation of impurities of bicalutamide, viz bical-sulfoxides (6), bical-deshydroxy (10), bical-desfluoro (10a), bical-2-fluoro (10b), and bical-3-fluoro (10c). Copyright Taylor & Francis Group, LLC.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 906008-93-3